Hjem › Ikke-småcellet lungekreft › South Carolina
Kliniske studier for Ikke-småcellet lungekreft i South Carolina
30 studier for Ikke-småcellet lungekreft søker deltakere på steder i South Carolina.
Byer i South Carolina
- Charleston16 studier
- Greenville15 studier
- Spartanburg6 studier
- Greer5 studier
- Easley4 studier
- Anderson4 studier
- Columbia3 studier
Offisiell studietekst (engelsk)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Medical University of South Carolina /ID# 273272, Charleston
- Saint Francis Cancer Center - Greenville /ID# 276368, Greenville
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT06568939Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Saint Joseph's/Candler - Bluffton Campus, Bluffton
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Bon Secours Saint Francis Hospital, Charleston
- og 15 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT04267848Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Bon Secours Hematology and Oncology, Greenville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06472245Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #9, Myrtle Beach
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT05176483Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Prisma Health Cancer Institute - Easley, Easley
- Gibbs Cancer Center-Gaffney, Gaffney
- og 9 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06498635A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Saint Joseph's Candler Health System ( Site 4010), Bluffton
- Medical University of South Carolina-Hollings Cancer Center ( Site 0045), Charleston
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06312137A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Medical University of South Carolina, Florence
- Medical University of South Carolina Health Lancaster Medical Center, Lancaster
RekruttererFase 3
Alder 18 til 100 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT05920356A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Medical University of South Carolina, Charleston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06667076Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Medical University of South Carolina, Charleston
- Lexington Medical Center, West Columbia
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06890598Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Greenville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT06357533A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- St Francis Cancer Center, Greenville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06875310Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- PRISMA Health/ITOR, Greenville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05983432Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Greenville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT06767514ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Carolina Urologic Research Center, Myrtle Beach
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Spartanburg Regional, Spartanburg
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06303505Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- MUSC Hollings Cancer Center, Charleston
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT06750185A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute, Greenville
- Lexington Medical Center, West Columbia
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06119581Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Greenville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07291037Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
- Medical University of South Carolina, Charleston
RekruttererFase 3
Alder 18 til 90 · Alle kjønn · Oppdatert 27. jul. 2026 · NCT06745908Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- AnMed Health Cancer Center, Anderson
- Saint Joseph's/Candler - Bluffton Campus, Bluffton
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- og 9 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05642572DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA03-0, Charleston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. mai 2026 · NCT06953089Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Ralph H Johnson VA Medical Center, Charleston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. mai 2026 · NCT06116682Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- AnMed Health Cancer Center, Anderson
- Saint Joseph's/Candler - Bluffton Campus, Bluffton
- Medical University of South Carolina, Charleston
- og 5 flere
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- AnMed Health Cancer Center, Anderson
RekruttererFase 2
18 Minutes · Alle kjønn · Oppdatert 5. mai 2026 · NCT06031688Phase 2 Study of Fingolimod in Lung Cancers
- Hollings Cancer Center at Medical University of South Carolina, Charleston
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. mar. 2026 · NCT06424067Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- AnMed Health Cancer Center, Anderson
- Beaufort Memorial Hospital, Beaufort
- Saint Joseph's/Candler - Bluffton Campus, Bluffton
- og 18 flere
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204GEMINI-NSCLC: NSCLC Biomarker Study
- The Medical University of South Carolina, Charleston
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 5. feb. 2026 · NCT05236114A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- Dren Investigational Site, Greenville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 7. jan. 2026 · NCT06999187A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 123, Charleston
- Research Site 108, Greenville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. nov. 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Greenville
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.